Piramal Pharma's revenue declined 9% YoY to Rs 20.4 billion (in line) for the quarter

(Photo source: Company website) Piramal Pharma delivered in-line revenue for Q2 FY62. However, it delivered a miss on Ebitda/PAT for the quarter. Higher operational costs impacted the quarter’s performance

To continue reading this story You must be an existing Premium User Already a Premium User? Sign In

See Full Page